Search results
Added:
7 months ago
Added:
1 year ago
RP-UN-CAR-GB-0166 / June 2024This programme features a compelling discussion between two distinguished experts, Prof Pam Taub (University of California, San Diego, US) and Prof Nikolaus Marx (University Hospital RWTH, Aachen, DE), chairperson responsible for the most recent ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes. Together, they delve into a critical…
View more
Added:
5 months ago
ADA 2025 - Once-monthly MariTide treatment demonstrates around 15% average weight reduction at 52 weeks in patients with obesity, with or without type 2 diabetes.We are joined by Dr Harold Bays (L-MARC Research Center, Louisville, US) to discuss a 52-week, placebo-controlled, phase 2 randomised study (NCT05669599) investigating the efficacy, safety and tolerability of different doses of once…
View more
Added:
2 years ago
EASD 2023 — In this short interview, Dr Samuel S Engel (Associate Vice President at Merck) discusses a study investigating the effectiveness and safety of efinopegdutide (MK-6024) in patients with nonalcoholic fatty liver disease and type 2 diabetes (NCT04944992).The phase IIa study randomized 145 participants (efinopegdutide, n = 72; semaglutide, n = 73). The majority (55.2%) of participants…
View more
Added:
5 months ago
ADA 2025 - Final results from the CATALYST trial show mifepristone significantly improved glucose control in patients with hypercortisolism and difficult-to-control diabetes.We are joined by Dr John Buse (University of North Carolina, Chapel Hill, US) to discuss phase 4 results from CATALYST (NCT05772169), a randomised, placebo-controlled, multi-center trial investigating the safety and efficacy…
View more
Added:
6 months ago
ERA 2025 - Real-world outcomes show switching from treatment with steroidal mineralocorticoid receptor antagonists (sMRAs) to finerenone is a safe option in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D).Dr Beatriz Fernandez Fernandez (Hospital Universitario Fundación Jiménez Dïaz, Madrid, ES) joins us to discuss real-world outcomes from a study investigating the effect of…
View more
Added:
3 weeks ago
AHA Scientific Sessions 2025 – Late-breaker host Dr Harriette Van Spall (McMaster University, CA) is joined by Prof Stephen Nicholls (Monash University, AU) to present the findings of this AHA late-breaking trial.This pre-specified analysis of the SURPASS-CVOT randomised clinical trial evaluates the comparative effects of once-weekly tirzepatide versus dulaglutide on heart failure outcomes in…
View more
Added:
6 months ago
ESC HF 25 - FIVE-STAR primary outcome is neutral, though finerenone was shown to significantly reduce UACR rates with a 29% greater reduction compared to placebo.We are joined by Dr Atsushi Tanaka (Saga University, Saga, JP) to discuss the findings from FIVE-STAR, a randomized trial investigating the effects of finerenone on vascular stiffness and cardiorenal biomarkers in patients with type 2…
View more
Added:
8 months ago
ACC 25 - SOUL shows oral semaglutide was superior to placebo in reducing the incidence of 3-point MACE in patients with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease.Late-breaker host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Dr Darren McGuire (UT Southwestern Medical Center, Dallas, US) to discuss the findings from the…
View more
Added:
8 months ago
ACC 25 - STRIDE shows subcutaneous semaglutide improved walking ability and related quality of life in patients with both type 2 diabetes and peripheral arterial disease (PAD) with intermittent claudication symptoms.Late-Breaker host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Dr Marc Bonaca (University of Colorado School of Medicine, Aurora, CO, US) to discuss the…
View more